CN106999447B - 氧化脂质及使用其的方法 - Google Patents

氧化脂质及使用其的方法 Download PDF

Info

Publication number
CN106999447B
CN106999447B CN201580064405.4A CN201580064405A CN106999447B CN 106999447 B CN106999447 B CN 106999447B CN 201580064405 A CN201580064405 A CN 201580064405A CN 106999447 B CN106999447 B CN 106999447B
Authority
CN
China
Prior art keywords
compound
group
fibrosis
alkyl
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580064405.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106999447A (zh
Inventor
E·K·伊斯海
I·门德尔
Y·萨莱姆
N·雅科夫
E·布赖特巴特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of CN106999447A publication Critical patent/CN106999447A/zh
Application granted granted Critical
Publication of CN106999447B publication Critical patent/CN106999447B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580064405.4A 2014-11-26 2015-11-26 氧化脂质及使用其的方法 Expired - Fee Related CN106999447B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085153P 2014-11-26 2014-11-26
US62/085,153 2014-11-26
PCT/IB2015/059134 WO2016084024A1 (en) 2014-11-26 2015-11-26 Oxidized lipids and methods of use thereof

Publications (2)

Publication Number Publication Date
CN106999447A CN106999447A (zh) 2017-08-01
CN106999447B true CN106999447B (zh) 2020-10-30

Family

ID=56073714

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580064405.4A Expired - Fee Related CN106999447B (zh) 2014-11-26 2015-11-26 氧化脂质及使用其的方法

Country Status (8)

Country Link
US (2) US9771385B2 (https=)
EP (1) EP3223806B1 (https=)
JP (1) JP6637044B2 (https=)
CN (1) CN106999447B (https=)
CA (1) CA2968504A1 (https=)
ES (1) ES2777533T3 (https=)
IL (1) IL252508A0 (https=)
WO (1) WO2016084024A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
EP3223824B1 (en) 2014-11-26 2021-01-06 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
WO2021199003A1 (en) * 2020-04-02 2021-10-07 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of inflammation or infectious disease caused by coronavirus infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089635A2 (en) * 1982-03-22 1983-09-28 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, process for preparation thereof and pharmaceutical composition of the same
CN1826122A (zh) * 2003-05-27 2006-08-30 脉管生物生长有限公司 氧化脂质及其在治疗炎性疾病中的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638578B2 (https=) 1973-05-18 1981-09-08
US4166132A (en) 1977-08-18 1979-08-28 Pfizer Inc. Antiviral amine derivatives of glycerol and propanediols
GB1572226A (en) 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
JPS58154512A (ja) 1982-03-09 1983-09-14 Takeda Chem Ind Ltd 血小板活性化因子抑制剤
JPS58164596A (ja) * 1982-03-22 1983-09-29 Fujisawa Pharmaceut Co Ltd 燐脂質誘導体、その製造法およびそれを含有する抗腫瘍剤
JPS58192825A (ja) * 1982-05-06 1983-11-10 Takeda Chem Ind Ltd グリセロール誘導体
JPS5993022A (ja) 1982-11-16 1984-05-29 Kao Corp ポリオ−ルエ−テル化合物およびその製造法ならびにこれを含有する化粧料
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
AT383130B (de) 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
JPH0617307B2 (ja) 1984-11-09 1994-03-09 武田薬品工業株式会社 抗腫瘍剤
US4827011A (en) 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
EP0225129B1 (en) 1985-11-29 1989-05-24 Takeda Chemical Industries, Ltd. Phospholipid derivatives, their production and use
WO1987005904A1 (en) 1986-03-24 1987-10-08 The University Of Sydney Antigenic analogues of platelet activating factor (paf)
JPH01502022A (ja) 1986-04-07 1989-07-13 ジ・アップジョン・カンパニー 駆虫薬第４級アルキルアシルヒドラゾン、使用方法および組成物
JPS6294A (ja) 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
ES2036210T3 (es) 1986-07-14 1993-05-16 Nippon Chemiphar Co., Ltd. Un procedimiento para la preparacion de un derivado de glicerol.
JPS6354386A (ja) 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPS63135395A (ja) 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
JPH01258691A (ja) 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JP2534894B2 (ja) 1988-06-24 1996-09-18 日本ケミファ株式会社 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤
JPH0248585A (ja) 1988-08-10 1990-02-19 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
JPH03258740A (ja) 1990-03-06 1991-11-19 Kao Corp 液体油、その製造法及びこれを含有する化粧料
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
JP2869572B2 (ja) 1990-05-14 1999-03-10 和光純薬工業株式会社 ホスファチジルコリン誘導体の製造方法
JP3128782B2 (ja) 1992-06-12 2001-01-29 科学技術振興事業団 架橋高分子薄膜の製造方法
US5561052A (en) 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
AU1751795A (en) 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
JP3364313B2 (ja) 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン／インジウム錯体及び陰イオン感応膜
JPH0859545A (ja) 1994-08-24 1996-03-05 Kao Corp カルボキシエチルエーテル誘導体及びこれを含有する洗浄剤組成物
JP4259611B2 (ja) 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
JPH08208548A (ja) 1995-02-01 1996-08-13 Kao Corp グリセリン誘導体の製造法
US5660855A (en) 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
EP0875247B1 (en) * 1997-04-18 2003-05-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for controlling the plasma level of lipoproteins
JP3781877B2 (ja) 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
US6414168B1 (en) 1998-12-28 2002-07-02 Caschem, Inc. Epoxidation of ricinic compounds using a phase-transfer catalyst
US6348583B1 (en) 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
AU2001249762B2 (en) 2000-03-31 2006-03-30 The Regents Of The University Of California A functional assay of high-density lipoprotein
WO2002041827A2 (en) 2000-11-24 2002-05-30 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
DE10155095A1 (de) 2001-11-09 2003-05-22 Cognis Deutschland Gmbh Alkyl(en)ylglycerinethercarbonsäuren
EP1460082A1 (en) * 2003-03-19 2004-09-22 Heidelberg Pharma Holding GmbH Phospholipid esters of clofarabine derivatives
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
PL1773352T3 (pl) 2004-07-09 2014-04-30 Vascular Biogenics Ltd Ulepszony sposób wytwarzania utlenionych fosfolipidów
US20060194765A1 (en) 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US8252775B2 (en) 2005-07-21 2012-08-28 The Board Of Trustees Of The Leland Stanford Junior University Method of treating multiple sclerosis with phosphocholine containing lipids
US8084209B2 (en) 2005-07-22 2011-12-27 Children's Hospital & Research Center Oakland HMGCR isoforms in prediction of efficacy and identification of cholesterol-modulating compounds
US20090074720A1 (en) 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
JP2009520730A (ja) * 2005-12-23 2009-05-28 ヤド・テヒノロギース・ゲーエムベーハー アレルギー性疾患を治療および予防するための手段および方法
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
JP2008037763A (ja) 2006-08-01 2008-02-21 Adeka Corp 抗菌剤及び抗菌剤組成物
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
CA2702437C (en) 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
EP2348864A4 (en) 2008-10-08 2013-07-31 Vascular Biogenics Ltd OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF
EP2826370A3 (en) 2008-11-06 2015-04-08 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
NZ601324A (en) 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
JP2013516457A (ja) 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Ｖｂ−２０１を用いた併用治療法
CA2847218C (en) 2011-09-01 2018-02-27 Vascular Biogenics Ltd. Formulations and dosage forms of oxidized phospholipids
ES2758923T3 (es) 2011-12-12 2020-05-07 Vascular Biogenics Ltd Tratamiento de esteatohepatitis no alcohólica
EP2814497A4 (en) 2012-02-16 2015-12-09 Vascular Biogenics Ltd METHOD FOR TREATING PSORIASIS AND VESSEL IGNITION
EP3223824B1 (en) 2014-11-26 2021-01-06 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089635A2 (en) * 1982-03-22 1983-09-28 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, process for preparation thereof and pharmaceutical composition of the same
CN1826122A (zh) * 2003-05-27 2006-08-30 脉管生物生长有限公司 氧化脂质及其在治疗炎性疾病中的应用

Also Published As

Publication number Publication date
WO2016084024A1 (en) 2016-06-02
JP6637044B2 (ja) 2020-01-29
EP3223806A4 (en) 2018-02-21
EP3223806A1 (en) 2017-10-04
CN106999447A (zh) 2017-08-01
EP3223806B1 (en) 2020-01-15
US20170369516A1 (en) 2017-12-28
JP2017537094A (ja) 2017-12-14
IL252508A0 (en) 2017-07-31
ES2777533T3 (es) 2020-08-05
CA2968504A1 (en) 2016-06-02
US10464957B2 (en) 2019-11-05
US9771385B2 (en) 2017-09-26
US20160304544A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US11524930B2 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
AU2014231649B2 (en) Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
BRPI0720478A2 (pt) Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
CN106999447B (zh) 氧化脂质及使用其的方法
JP2025164962A (ja) ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
US10206936B2 (en) Oxidized lipids and treatment or prevention of fibrosis
HK1235297A1 (en) Oxidized lipids and methods of use thereof
CN111440150A (zh) 一种一氧化氮供体型法舒地尔衍生物及其制备方法和用途
HK1242621B (en) Oxidized lipids and methods of use thereof
HK1242621A1 (en) Oxidized lipids and methods of use thereof
HK1235296A1 (en) Oxidized lipids and treatment or prevention of fibrosis
HK1220440B (en) Substituted aromatic compounds
HK1220439B (en) Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1235297

Country of ref document: HK

CB02 Change of applicant information

Address after: Israel Modein

Applicant after: VASCULAR BIOGENICS LTD.

Address before: Israel Orr Yehuda

Applicant before: VASCULAR BIOGENICS LTD.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201030

CF01 Termination of patent right due to non-payment of annual fee